JW (Cayman) Therapeutics Co. Ltd (HKG:2126)

HKG:2126 Revenue

In the year 2025, JW (Cayman) Therapeutics Co. had annual revenue of 283.65M CNY with 79.28% growth. JW (Cayman) Therapeutics Co. had revenue of 177.31M in the half year ending December 31, 2025, with 105.89% growth.

• Revenue: 283.65M CNY
• Revenue Growth: +79.28%
• P/S Ratio: 2.04
• Revenue / Employee: 903.35K CNY
• Employees: 314
• Market Cap: 645.37M HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	283.65M	125.44M	79.28%
Dec 31, 2024	158.22M	-15.64M	-8.99%
Dec 31, 2023	173.86M	28.15M	19.32%
Dec 31, 2022	145.70M	114.91M	373.10%
Dec 31, 2021	30.80M	-	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 16, 2026

Data Sources Report a data error